BMY Stock Chart & Stats
$1120.18
$0.00(0.00%)
At close: 4:00 PM EDT
$1120.18
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$777.01 - $1,350.00
Previous CloseN/A
Volume0.00
Average Volume (3M)159.00
Market Cap
$2.31T
Enterprise Value$151.99B
Total Cash (Recent Filing)$11.07B
Total Debt (Recent Filing)$43.12B
Price to Earnings (P/E)13.3
Beta<0.01
Next Earnings
Feb 04, 2027EPS Estimate
30.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.54
Shares Outstanding2,042,714,600
10 Day Avg. Volume95
30 Day Avg. Volume159
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,234.40Price Target Upside10.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)118.2
Revenue Forecast (FY)$931.22B
Bulls Say, Bears Say
Bulls Say
Diversified Growth PortfolioA broad group of billion-dollar growth medicines reduces reliance on any single product and gives BMS multiple established revenue engines. This diversification supports portfolio resilience, creates opportunities for cross-market expansion, and strengthens the company’s ability to absorb pressure in older brands.
Strong Cash GenerationRobust operating and free cash flow indicates that reported earnings are substantially backed by cash generation. This provides durable capacity to service debt, invest in research and development, pursue business development, support manufacturing expansion, and return capital while maintaining operating flexibility.
Pipeline RenewalPositive registrational readouts across multiple therapeutic areas improve the prospects for replacing maturing products and broadening future revenue sources. A productive late-stage pipeline can support portfolio renewal, reduce dependence on current blockbusters, and provide additional growth options over several years.
Bears Say
Eliquis Exclusivity LossEliquis is a major revenue contributor, so its expected loss of exclusivity creates a defined and material headwind to future sales. The anticipated step-down will require growth medicines, launches, and pipeline products to scale sufficiently to offset the erosion and protect earnings durability.
Elevated LeverageElevated leverage reduces financial flexibility even though the balance-sheet trajectory has improved. A highly levered capital structure leaves less room to absorb weaker product cycles, fund acquisitions, or sustain shareholder returns if profitability softens, while increasing the importance of dependable cash generation.
CAR-T Safety And Execution RiskThe Zolacel pause and fatal event create meaningful clinical, regulatory, and execution uncertainty around an otherwise potentially important autoimmune CAR-T program. Restarting trials requires work with authorities, and delays or further safety concerns could defer development progress and limit the platform’s contribution.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $777.01 and its highest was $1350.00 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $2.31T.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Feb 04, 2027 which is in 98 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Oct 29, 2026. The company reported $25.195 earnings per share for the quarter, beating the consensus estimate of $20.51 by $4.684.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb does not currently pay dividends.
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 30.21.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,042,714,600 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $25.195 in its last earnings report, beating expectations of $20.51. Following the earnings report the stock price went up 1.406%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in MX:BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,234.40 (10.20% Upside)
$1,234.40 (10.20% Upside)
Blogger Sentiment
Bullish
MX:BMY Sentiment 87%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth $8.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.74%
12-Months-Change
Fundamentals
Return on Equity
46.75%
Trailing 12-Months
Asset Growth
-7.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
BMY Company Deck
BMY Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall. Management reported 7% total revenue growth, 12% growth in the growth portfolio, strong performance from multiple key brands, raised full-year guidance, substantial cash generation, and several positive late-stage pipeline readouts. The principal challenges were the upcoming Eliquis loss of exclusivity, declines in parts of the legacy portfolio and Opdivo, execution issues for Cobenfy, uncertainty around the higher admilparant dose, and the Zolacel program pause following a fatal event. Highlights significantly outweighed the lowlights.View all MX:BMY earnings summariesBMY Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$1,234.40
▲(10.20% Upside)